PDF下载 ( 2577 KB)
Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021)
-
摘要: 2015年我国第一个原发性硬化性胆管炎(PSC)的专家共识颁布。近年来PSC的临床研究提供了PSC新的研究数据和资料。为此, 中华医学会肝病学分会自身免疫性肝病学组组织专家组对近年来的文献证据进行了评估, 制定了本指南。本指南共有PSC推荐意见21条。为了利于鉴别PSC和IgG4相关硬化性胆管炎(IgG4-SC), 也附有IgG4-SC的10条推荐意见。本指南的目的是为临床PSC和IgG4-SC的诊治提供参考和指导。
-
关键词:
- 原发性硬化性胆管炎 /
- IgG4相关性硬化性胆管炎 /
- 诊断 /
- 治疗 /
- 实践指南
Abstract: In 2015, the first Chinese consensus on the diagnosis and management of primary sclerosing cholangitis was issued. In the past years, more data have emerged from the literature. Herein, the Autoimmune Liver Disease Group of the Chinese Society of Hepatology organized an expert group to review the evidence and updated the recommendations to formulate the guidelines. There are 21 recommendations on PSC clinical practice. To facilitate the differentiation between PSC and IgG4-related sclerosing cholangitis, 10 recommendations on IgG4-SC are also attached. These guidelines aim to provide a working reference for the management of PSC and IgG4-SC. -
表 1 推荐意见的证据等级和推荐强度等级
级别 详细说明 证据质量 高(A) 进一步研究不可能改变对该疗效评估结果的可信度 中(B) 进一步研究有可能影响该疗效评估结果的可信度, 且可能改变该评估结果 低或非常低(C) 进一步研究很有可能影响该疗效评估结果的可信度, 且很可能改变该评估结果 推荐强度 强(1) 明确显示干预措施利大于弊或者弊大于利 弱(2) 利弊不确定或无论质量高低的证据均显示利弊相当 
下载: 导出CSV
表 2 继发性胆管炎的病因分类
病因分类 常见病因 慢性梗阻 胆道结石胆管狭窄(手术或慢性胰腺炎继发)肝移植后吻合口狭窄良恶性肿瘤 感染性疾病 寄生虫感染病毒感染(HIV、巨细胞病毒等) 药物、毒物 意外在胆管内注入酒精或福尔马林药物性损伤(氯胺酮、塞来昔布、七氟烷、阿莫西林克拉维酸、阿托伐他汀、英夫利昔单抗等) 免疫性 IgG4相关自身胰腺炎或IgG4相关硬化性胆管炎嗜酸性粒细胞性胆管炎肥大细胞性胆管疾病淀粉样变性Bechet’s病 缺血性胆管疾病 肝移植后肝动脉血栓肝移植排斥反应肝动脉内插管化疗肝动脉栓塞化疗系统性血管炎放射损伤 缺血样胆管疾病 危重症患者继发性硬化性胆管炎(创伤、烧伤、心胸手术、呼吸系统疾病、HELLP综合征、胰腺炎、急性心肌梗死、蛛网膜下腔出血、脑出血等)
下载: 导出CSV
表 3 IgG4-SC诊断标准(2020版)
诊断指标 Ⅰ. 肝内/外胆管狭窄 a. ERC b. MRCP Ⅱ. 胆道壁增厚 a. EUS/IDUS b. CT/MRI/US Ⅲ. 血清学 血清IgG水平升高(＞135 mg/dL) Ⅳ. 病理学：满足(i)-(v)的不同组合 a. 观察到(i)、(ii)和(v) b. 观察到(v) c. 观察到(i)、(ii)、(v)以及(iii)和/或(iv) (i) 明显的淋巴浆细胞浸润和纤维化 (ii) IgG4+浆细胞≥10个/HPF (iii) 席纹状纤维化 (iv) 闭塞性静脉炎 (v) 未观察到肿瘤细胞 Ⅴ. 其他脏器受累 a.Ⅰ型自身免疫性胰腺炎 b. IgG4相关性泪腺炎/唾液腺炎(Mikulicz病)、IgG4相关的腹膜后纤维化、IgG4相关的肾脏病变 Ⅵ. 糖皮质激素治疗有效 诊断 Ⅰ. 确诊 胆道成像1、2型 Ⅰa/b+Ⅱa/b+Ⅲ/Ⅵ (1) Ⅴa+ 胆道成像3、4型 Ⅰa+Ⅱa+Ⅳb+Ⅲ/Ⅵ (2) Ⅴa- 胆道成像1、2、3、4型 Ⅰa+Ⅱa+Ⅲ+Ⅳa/Ⅵ (3)明确病理诊 Ⅳc Ⅱ. 拟诊 胆道成像1、2型 Ⅰa/b+Ⅱa/b (1) Ⅴa+ 胆道成像3、4型 Ⅰa+Ⅱa+Ⅳb (2) Ⅴa- 胆道成像1、2、3、4型 Ⅰa/b+Ⅱb+Ⅵ Ⅰa+Ⅱa+Ⅳa Ⅰa+Ⅱa+Ⅲ+Ⅵ Ⅰb+Ⅱa+Ⅲ+Ⅵ Ⅲ. 疑诊 胆道成像3、4型 Ⅰa/b+Ⅱa (1) Ⅴa+ 胆道成像1、2、3、4型 Ⅰb+Ⅱb+Ⅲ (2) Ⅴa- Ⅰa+Ⅱa+Ⅲ/Ⅴb/Ⅵ Ⅰb+Ⅱb+Ⅲ+Ⅵ
下载: 导出CSV
表 4 IgG4-SC与PSC鉴别要点
指标 PSC IgG4-SC 临床特征 男性多发 + ++ 青年发病 ++ + 血清IgG4水平升高 -/+ ++ 合并IBD ++ - 合并AIP或其他IgG4-RD - ++ 糖皮质激素治疗有效 - +++ 组织学 肝脏胆道组织学 “洋葱皮样”胆管纤维化 + - 席纹样胆管纤维化 - + 闭塞性血管炎 - + ＞10个IgG4+浆细胞/HPF -/+ +++ 壶腹部活检组织 - ＞10个IgG4+浆细胞/HPF +++ 影像学特征 MRCP 胆管狭窄长度 +(＜5 mm) ++(＞10 mm) 狭窄近端胆管扩张 ++ + 外周胆管枯树枝样改变 ++ - 胆管假憩室样改变 ++ - IDUS 胆管狭窄处管壁非对称增厚 ++ +/- 胆管狭窄处以外管壁增厚 - ++ 胆管壁层次消失 ++ +/- 胆管内壁不规则 + - PCOS 胆管黏膜表面血管密度 + ++ 胆管黏膜表面血管迂曲扩张 - ++ 胆管黏膜表面纤维瘢痕组织 ++ -
下载: 导出CSV
-
[1] BAMBHA K, KIM WR, TALWALKAR J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community[J]. Gastroenterology, 2003, 125(5): 1364-1369. DOI: 10.1016/j.gastro.2003.07.011. [2] CHAPMAN MH, THORBURN D, HIRSCHFIELD GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis[J]. Gut, 2019, 68(8): 1356-1378. DOI: 10.1136/gutjnl-2018-317993. [3] TRIVEDI PJ, HIRSCHFIELD GM. Recent advances in clinical practice: Epidemiology of autoimmune liver diseases[J]. Gut, 2021, 70(10): 1989-2003. DOI: 10.1136/gutjnl-2020-322362. [4] ISAYAMA H, TAZUMA S, KOKUDO N, et al. Clinical guidelines for primary sclerosing cholangitis 2017[J]. J Gastroenterol, 2018, 53(9): 1006-1034. DOI: 10.1007/s00535-018-1484-9. [5] ANG TL, FOCK KM, NG TM, et al. Clinical profile of primary sclerosing cholangitis in Singapore[J]. J Gastroenterol Hepatol, 2002, 17(8): 908-913. DOI: 10.1046/j.1440-1746.2002.02835.x. [6] MEHTA TI, WEISSMAN S, FUNG BM, et al. Global incidence, prevalence and features of primary sclerosing cholangitis: A systematic review and meta-analysis[J]. Liver Int, 2021, 41(10): 2418-2426. DOI: 10.1111/liv.15007. [7] KARLSEN TH, FOLSERAAS T, THORBURN D, et al. Primary sclerosing cholangitis - a comprehensive review[J]. J Hepatol, 2017, 67(6): 1298-1323. DOI: 10.1016/j.jhep.2017.07.022. [8] DEAN G, HANAUER S, LEVITSKY J. The role of the intestine in the pathogenesis of primary sclerosing cholangitis: Evidence and therapeutic implications[J]. Hepatology, 2020, 72(3): 1127-1138. DOI: 10.1002/hep.31311. [9] GUICCIARDI ME, TRUSSONI CE, La RUSSO NF, et al. The spectrum of reactive cholangiocytes in primary sclerosing cholangitis[J]. Hepatology, 2020, 71(2): 741-748. DOI: 10.1002/hep.31067. [10] de KRIJGER M, WILDENBERG ME, de JONGE WJ, et al. Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis[J]. J Hepatol, 2019, 71(3): 603-615. DOI: 10.1016/j.jhep.2019.05.006. [11] KUMMEN M, THINGHOLM LB, RVHLEMANN MC, et al. Altered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis[J]. Gastroenterology, 2021, 160(5): 1784-1798. e0. DOI: 10.1053/j.gastro.2020.12.058. [12] LEMOINNE S, KEMGANG A, BEN BELKACEM K, et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis[J]. Gut, 2020, 69(1): 92-102. DOI: 10.1136/gutjnl-2018-317791. [13] LIU Q, LI B, LI Y, et al. Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis[J]. Gut, 2021. DOI: 10.1136/gutjnl-2020-323565.[Online ahead of print] [14] LIWINSKI T, ZENOUZI R, JOHN C, et al. Alterations of the bile microbiome in primary sclerosing cholangitis[J]. Gut, 2020, 69(4): 665-672. DOI: 10.1136/gutjnl-2019-318416. [15] NAKAMOTO N, SASAKI N, AOKI R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis[J]. Nat Microbiol, 2019, 4(3): 492-503. DOI: 10.1038/s41564-018-0333-1. [16] KARLSEN TH, FOLSERAAS T, THORBURN D, et al. Primary sclerosing cholangitis - a comprehensive review[J]. J Hepatol, 2017, 67(6): 1298-1323. DOI: 10.1016/j.jhep.2017.07.022. [17] SONG J, LI Y, BOWLUS CL, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis (PSC): A comprehensive review[J]. Clin Rev Allergy Immunol, 2020, 58(1): 134-149. DOI: 10.1007/s12016-019-08764-7. [18] de VALLE MB, BJÖRNSSON E, LINDKVIST B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort[J]. Liver Int, 2012, 32(3): 441-448. DOI: 10.1111/j.1478-3231.2011.02614.x. [19] LINDOR KD, KOWDLEY KV, HARRISON ME, et al. ACG clinical guideline: Primary sclerosing cholangitis[J]. Am J Gastroenterol, 2015, 110(5): 646-659; quiz 660. DOI: 10.1038/ajg.2015.112. [20] HIRANO K, TADA M, ISAYAMA H, et al. Clinical features of primary sclerosing cholangitis with onset age above 50 years[J]. J Gastroenterol, 2008, 43(9): 729-733. DOI: 10.1007/s00535-008-2216-3. [21] TANAKA A, TAZUMA S, OKAZAKI K, et al. Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan[J]. J Hepatobiliary Pancreat Sci, 2014, 21(1): 43-50. DOI: 10.1002/jhbp.50. [22] KOVA C Č JD, WEBER MA. Primary biliary cirrhosis and primary sclerosing cholangitis: An update on MR Imaging findings with recent developments[J]. J Gastrointestin Liver Dis, 2016, 25(4): 517-524. DOI: 10.15403/jgld.2014.1121.254.vac. [23] ANGULO P, PEARCE DH, JOHNSON CD, et al. Magnetic resonance cholangiography in patients with biliary disease: Its role in primary sclerosing cholangitis[J]. J Hepatol, 2000, 33(4): 520-527. DOI: 10.1034/j.1600-0641.2000.033004520.x. [24] BERSTAD AE, AABAKKEN L, SMITH HJ, et al. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2006, 4(4): 514-520. DOI: 10.1016/j.cgh.2005.10.007. [25] European Society of Gastrointestinal Endoscopy; European Association for the Study of the Liver. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline[J]. J Hepatol, 2017, 66(6): 1265-1281. DOI: 10.1016/j.jhep.2017.02.013. [26] SARCOGNATO S, SACCHI D, GRILLO F, et al. Autoimmune biliary diseases: Primary biliary cholangitis and primary sclerosing cholangitis[J]. Pathologica, 2021, 113(3): 170-184. DOI: 10.32074/1591-951X-245. [27] BURAK KW, ANGULO P, LINDOR KD. Is there a role for liver biopsy in primary sclerosing cholangitis?[J]. Am J Gastroenterol, 2003, 98(5): 1155-1158. DOI: 10.1111/j.1572-0241.2003.07401.x. [28] de VRIES EM, de KRIJGER M, FÄRKKILÄ M, et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study[J]. Hepatology, 2017, 65(3): 907-919. DOI: 10.1002/hep.28963. [29] de VRIES EM, VERHEIJ J, HUBSCHER SG, et al. Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis[J]. J Hepatol, 2015, 63(5): 1212-1219. DOI: 10.1016/j.jhep.2015.06.008. [30] PORTMANN B, ZEN Y. Inflammatory disease of the bile ducts-cholangiopathies: Liver biopsy challenge and clinicopathological correlation[J]. Histopathology, 2012, 60(2): 236-248. DOI: 10.1111/j.1365-2559.2011.03853.x. [31] WEISMVLLER TJ, TRIVEDI PJ, BERGQUIST A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis[J]. Gastroenterology, 2017, 152(8): 1975-1984. e8. DOI: 10.1053/j.gastro.2017.02.038. [32] NAKAZAWA T, NOTOHARA K, TAZUMA S, et al. The 2016 diagnostic criteria for primary sclerosing cholangitis[J]. J Gastroenterol, 2017, 52(7): 838-844. DOI: 10.1007/s00535-016-1286-x. [33] PONSIOEN CY, ASSIS DN, BOBERG KM, et al. Defining primary sclerosing cholangitis: Results from an International Primary Sclerosing Cholangitis Study Group Consensus Process[J]. Gastroenterology, 2021, 161(6): 1764-1775. e5. DOI: 10.1053/j.gastro.2021.07.046. [34] BROOLING J, LEAL R. Secondary sclerosing cholangitis: A review of recent literature[J]. Curr Gastroenterol Rep, 2017, 19(9): 44. DOI: 10.1007/s11894-017-0583-8. [35] RUEMMELE P, HOFSTAEDTER F, GELBMANN CM. Secondary sclerosing cholangitis[J]. Nat Rev Gastroenterol Hepatol, 2009, 6(5): 287-295. DOI: 10.1038/nrgastro.2009.46. [36] KAMISAWA T, NAKAZAWA T, TAZUMA S, et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis[J]. J Hepatobiliary Pancreat Sci, 2019, 26(1): 9-42. DOI: 10.1002/jhbp.596. [37] ZHOU T, LENZEN H, DOLD L, et al. Primary sclerosing cholangitis with moderately elevated serum-IgG4 - characterization and outcome of a distinct variant phenotype[J]. Liver Int, 2021, 41(12): 2924-2933. DOI: 10.1111/liv.15028. [38] MANGANIS CD, CHAPMAN RW, CULVER EL. Review of primary sclerosing cholangitis with increased IgG4 levels[J]. World J Gastroenterol, 2020, 26(23): 3126-3144. DOI: 10.3748/wjg.v26.i23.3126. [39] MEHTA TI, WEISSMAN S, FUNG BM, et al. Global incidence, prevalence and features of primary sclerosing cholangitis: A systematic review and meta-analysis[J]. Liver Int, 2021, 41(10): 2418-2426. DOI: 10.1111/liv.15007. [40] TANAKA A, TAZUMA S, OKAZAKI K, et al. Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan[J]. J Hepatobiliary Pancreat Sci, 2014, 21(1): 43-50. DOI: 10.1002/jhbp.50. [41] TANAKA A, TAZUMA S, OKAZAKI K, et al. Clinical profiles of patients with primary sclerosing cholangitis in the elderly[J]. J Hepatobiliary Pancreat Sci, 2015, 22(3): 230-236. DOI: 10.1002/jhbp.194. [42] MERTZ A, NGUYEN NA, KATSANOS KH, et al. Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: An update of the evidence[J]. Ann Gastroenterol, 2019, 32(2): 124-133. DOI: 10.20524/aog.2019.0344. [43] de VRIES AB, JANSE M, BLOKZIJL H, et al. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis[J]. World J Gastroenterol, 2015, 21(6): 1956-1971. DOI: 10.3748/wjg.v21.i6.1956. [44] ATTAUABI M, ZHAO M, BENDTSEN F, et al. Systematic review with Meta-analysis: The impact of Co-occurring immune-mediated inflammatory diseases on the disease course of inflammatory bowel diseases[J]. Inflamm Bowel Dis, 2021, 27(6): 927-939. DOI: 10.1093/ibd/izaa167. [45] WIJNANDS AM, de JONG ME, LUTGENS M, et al. Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: Systematic review and Meta-analysis[J]. Gastroenterology, 2021, 160(5): 1584-1598. DOI: 10.1053/j.gastro.2020.12.036. [46] TRIVEDI PJ, CROTHERS H, MYTTON J, et al. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age[J]. Gastroenterology, 2020, 159(3): 915-928. DOI: 10.1053/j.gastro.2020.05.049. [47] GUERRA I, BUJANDA L, CASTRO J, et al. Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicentre retrospective cohort study[J]. J Crohns Colitis, 2019, 13(12): 1492-1500. DOI: 10.1093/ecco-jcc/jjz094. [48] BOONSTRA K, WEERSMA RK, van ERPECUM KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis[J]. Hepatology, 2013, 58(6): 2045-2055. DOI: 10.1002/hep.26565. [49] JORGENSEN RA, LINDOR KD, SARTIN JS, et al. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis[J]. J Clin Gastroenterol, 1995, 20(3): 215-219. DOI: 10.1097/00004836-199504000-00011. [50] ANGULO P, GRANDISON GA, FONG DG, et al. Bone disease in patients with primary sclerosing cholangitis[J]. Gastroenterology, 2011, 140(1): 180-188. DOI: 10.1053/j.gastro.2010.10.014. [51] GUICHELAAR MM, MALINCHOC M, SIBONGA J, et al. Bone metabolism in advanced cholestatic liver disease: Analysis by bone histomorphometry[J]. Hepatology, 2002, 36(4 Pt 1): 895-903. DOI: 10.1053/jhep.2002.36357. [52] ANGULO P, THERNEAU TM, JORGENSEN A, et al. Bone disease in patients with primary sclerosing cholangitis: Prevalence, severity and prediction of progression[J]. J Hepatol, 1998, 29(5): 729-735. DOI: 10.1016/s0168-8278(98)80253-5. [53] KELLER S, ITTRICH H, SCHRAMM C, et al. Diffusion-weighted MRI for detection of hepatic osteodystrophy in primary sclerosing cholangitis: A comparison study with dual-energy X-ray absorptiometry[J]. Jpn J Radiol, 2016, 34(10): 677-683. DOI: 10.1007/s11604-016-0573-z. [54] CAMPBELL MS, LICHTENSTEIN GR, RHIM AD, et al. Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis[J]. Liver Int, 2005, 25(2): 311-316. DOI: 10.1111/j.1478-3231.2005.01075.x. [55] QIU ML, XIE Y, WANG XH, et al. Practice guideline for patients with osteoporosis[J]. Chin J Intern Med, 2020, 59(12): 953-959. DOI: 10.3760/cma.j.cn112138-20200904-00792.邱敏丽, 谢雅, 王晓红, 等. 骨质疏松症患者实践指南[J]. 中华内科杂志, 2020, 59(12): 953-959. DOI: 10.3760/cma.j.cn112138-20200904-00792. [56] SCHRUMPF E, BOBERG KM. Hepatic and extrahepatic malignancies and primary sclerosing cholangitis[J]. Gut, 2003, 52(2): 165. DOI: 10.1136/gut.52.2.165. [57] BERGQUIST A, EKBOM A, OLSSON R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis[J]. J Hepatol, 2002, 36(3): 321-327. DOI: 10.1016/s0168-8278(01)00288-4. [58] CHARATCHAROENWITTHAYA P, ENDERS FB, HALLING KC, et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis[J]. Hepatology, 2008, 48(4): 1106-1117. DOI: 10.1002/hep.22441. [59] RAZUMILAVA N, GORES GJ, LINDOR KD. Cancer surveillance in patients with primary sclerosing cholangitis[J]. Hepatology, 2011, 54(5): 1842-1852. DOI: 10.1002/hep.24570. [60] EATON JE, BARR FRITCHER EG, GORES GJ, et al. Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis[J]. Am J Gastroenterol, 2015, 110(2): 299-309. DOI: 10.1038/ajg.2014.433. [61] BOWLUS CL, LIM JK, LINDOR KD. AGA clinical practice update on surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis: Expert review[J]. Clin Gastroenterol Hepatol, 2019, 17(12): 2416-2422. DOI: 10.1016/j.cgh.2019.07.011. [62] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases[J]. J Hepatol, 2009, 51(2): 237-267. DOI: 10.1016/j.jhep.2009.04.009. [63] EATON JE, THACKERAY EW, LINDOR KD. Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis[J]. Am J Gastroenterol, 2012, 107(3): 431-439. DOI: 10.1038/ajg.2011.361. [64] LINDOR KD, KOWDLEY KV, HARRISON ME. ACG clinical guideline: Primary sclerosing cholangitis[J]. Am J Gastroenterol, 2015, 110(5): 646-659; quiz 660. DOI: 10.1038/ajg.2015.112. [65] Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006中华医学会肝病学会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. [66] CHAZOUILLÈRES O, POUPON R, CAPRON JP, et al. Ursodeoxycholic acid for primary sclerosing cholangitis[J]. J Hepatol, 1990, 11(1): 120-123. DOI: 10.1016/0168-8278(90)90281-u. [67] LINDSTRÖM L, HULTCRANTZ R, BOBERG KM, et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2013, 11(7): 841-846. DOI: 10.1016/j.cgh.2012.12.032. [68] LINDSTRÖM L, BOBERG KM, WIKMAN O, et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia[J]. Aliment Pharmacol Ther, 2012, 35(4): 451-457. DOI: 10.1111/j.1365-2036.2011.04966.x. [69] EATON JE, SILVEIRA MG, PARDI DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis[J]. Am J Gastroenterol, 2011, 106(9): 1638-1645. DOI: 10.1038/ajg.2011.156. [70] LINDOR KD, KOWDLEY KV, LUKETIC VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis[J]. Hepatology, 2009, 50(3): 808-814. DOI: 10.1002/hep.23082. [71] CULLEN SN, RUST C, FLEMING K, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective[J]. J Hepatol, 2008, 48(5): 792-800. DOI: 10.1016/j.jhep.2007.12.023. [72] OLSSON R, BOBERG KM, DE MUCKADELL OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study[J]. Gastroenterology, 2005, 129(5): 1464-1472. DOI: 10.1053/j.gastro.2005.08.017. [73] STERLING RK, SALVATORI JJ, LUKETIC VA, et al. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis[J]. Aliment Pharmacol Ther, 2004, 20(9): 943-949. DOI: 10.1111/j.1365-2036.2004.02214.x. [74] SJÖQVIST U, TRIBUKAIT B, OST A, et al. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: A prospective, double-blind, randomized controlled pilot study[J]. Anticancer Res, 2004, 24(5B): 3121-3127. http://so.med.wanfangdata.com.cn/ViewHTML/PeriodicalPaper_JJ028407017.aspx [75] FÄRKKILÄ M, KARVONEN AL, NURMI H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial[J]. Hepatology, 2004, 40(6): 1379-1386. DOI: 10.1002/hep.20457. [76] PARDI DS, LOFTUS EV Jr, KREMERS WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis[J]. Gastroenterology, 2003, 124(4): 889-893. DOI: 10.1053/gast.2003.50156. [77] MITCHELL SA, BANSI DS, HUNT N, et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis[J]. Gastroenterology, 2001, 121(4): 900-907. DOI: 10.1053/gast.2001.27965. [78] HARNOIS DM, ANGULO P, JORGENSEN RA, et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis[J]. Am J Gastroenterol, 2001, 96(5): 1558-1562. DOI: 10.1111/j.1572-0241.2001.03777.x. [79] van HOOGSTRATEN HJ, VLEGGAAR FP, BOLAND GJ, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: A randomized double-blind pilot study. Belgian-Dutch PSC Study Group[J]. Am J Gastroenterol, 2000, 95(8): 2015-2022. DOI: 10.1111/j.1572-0241.2000.02267.x. [80] van HOOGSTRATEN HJ, WOLFHAGEN FH, van de MEEBERG PC, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: Results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses[J]. J Hepatol, 1998, 29(3): 417-423. DOI: 10.1016/s0168-8278(98)80059-7. [81] LINDOR KD. Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group[J]. N Engl J Med, 1997, 336(10): 691-695. DOI: 10.1056/NEJM199703063361003. [82] van de MEEBERG PC, WOLFHAGEN FH, van BERGE-HENEGOUWEN GP, et al. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: Biliary enrichment and biochemical response[J]. J Hepatol, 1996, 25(6): 887-894. DOI: 10.1016/s0168-8278(96)80293-5. [83] de MARIA N, COLANTONI A, ROSENBLOOM E, et al. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period[J]. Hepatogastroenterology, 1996, 43(12): 1472-1479. http://www.ncbi.nlm.nih.gov/pubmed/8975951 [84] STIEHL A, WALKER S, STIEHL L, et al. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period[J]. J Hepatol, 1994, 20(1): 57-64. DOI: 10.1016/s0168-8278(05)80467-2. [85] BEUERS U, SPENGLER U, KRUIS W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial[J]. Hepatology, 1992, 16(3): 707-714. DOI: 10.1002/hep.1840160315. [86] CHEN W, GLUUD C. Bile acids for primary sclerosing cholangitis[J]. Cochrane Database Syst Rev, 2003, 2: CD003626. DOI: 10.1002/14651858.CD003626. [87] POROPAT G, GILJACA V, STIMAC D, et al. Bile acids for primary sclerosing cholangitis[J]. Cochrane Database Syst Rev, 2011, 1: CD003626. DOI: 10.1002/14651858.CD003626.pub2. [88] TRIANTOS CK, KOUKIAS NM, NIKOLOPOULOU VN, et al. Meta-analysis: Ursodeoxycholic acid for primary sclerosing cholangitis[J]. Aliment Pharmacol Ther, 2011, 34(8): 901-910. DOI: 10.1111/j.1365-2036.2011.04822.x. [89] ZHU GQ, SHI KQ, HUANG GQ, et al. A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis[J]. Oncotarget, 2015, 6(29): 26757-26769. DOI: 10.18632/oncotarget.5610. [90] SAFFIOTI F, GURUSAMY KS, HAWKINS N, et al. Pharmacological interventions for primary sclerosing cholangitis: An attempted network meta-analysis[J]. Cochrane Database Syst Rev, 2017, 3: CD011343. DOI: 10.1002/14651858.CD011343.pub2. [91] ASHRAF I, CHOUDHARY A, ARIF M, et al. Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: A meta-analysis[J]. Indian J Gastroenterol, 2012, 31(2): 69-74. DOI: 10.1007/s12664-012-0175-3. [92] OTHMAN MO, DUNKELBERG J, ROY PK. Urosdeoxycholic acid in primary sclerosing cholangitis: A meta-analysis and systematic review[J]. Arab J Gastroenterol, 2012, 13(3): 103-110. DOI: 10.1016/j.ajg.2012.06.011. [93] HANSEN JD, KUMAR S, LO WK, et al. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: A meta-analysis[J]. Dig Dis Sci, 2013, 58(11): 3079-3087. DOI: 10.1007/s10620-013-2772-0. [94] FICKERT P, HIRSCHFIELD GM, DENK G, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis[J]. J Hepatol, 2017, 67(3): 549-558. DOI: 10.1016/j.jhep.2017.05.009. [95] WUNSCH E, TROTTIER J, MILKIEWICZ M, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis[J]. Hepatology, 2014, 60(3): 931-940. DOI: 10.1002/hep.27074. [96] ANGULO P, BATTS KP, JORGENSEN RA, et al. Oral budesonide in the treatment of primary sclerosing cholangitis[J]. Am J Gastroenterol, 2000, 95(9): 2333-2337. DOI: 10.1111/j.1572-0241.2000.02323.x. [97] GILJACA V, POROPAT G, STIMAC D, et al. Glucocorticosteroids for primary sclerosing cholangitis[J]. Cochrane Database Syst Rev, 2010, (1): CD004036. DOI: 10.1002/14651858.CD004036.pub3. [98] CHEN W, GLUUD C. Glucocorticosteroids for primary sclerosing cholangitis[J]. Cochrane Database Syst Rev, 2004, 3: CD004036. DOI: 10.1002/14651858.CD004036.pub2. [99] BOBERG KM, EGELAND T, SCHRUMPF E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients[J]. Scand J Gastroenterol, 2003, 38(9): 991-995. DOI: 10.1080/00365520310005172. [100] FLOREANI A, RIZZOTTO ER, FERRARA F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome[J]. Am J Gastroenterol, 2005, 100(7): 1516-1522. DOI: 10.1111/j.1572-0241.2005.41841.x. [101] KNOX TA, KAPLAN MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis[J]. Gastroenterology, 1994, 106(2): 494-499. DOI: 10.1016/0016-5085(94)90610-6. [102] van THIEL DH, CARROLL P, ABU-ELMAGD K, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: Results of an open-label preliminary trial[J]. Am J Gastroenterol, 1995, 90(3): 455-459. [103] HOMMES DW, ERKELENS W, PONSIOEN C, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis[J]. J Clin Gastroenterol, 2008, 42(5): 522-526. DOI: 10.1097/MCG.0b013e3181662426. [104] TALWALKAR JA, ANGULO P, KEACH JC, et al. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis[J]. Am J Gastroenterol, 2005, 100(2): 308-312. DOI: 10.1111/j.1572-0241.2005.40484.x. [105] TALWALKAR JA, GOSSARD AA, KEACH JC, et al. Tacrolimus for the treatment of primary sclerosing cholangitis[J]. Liver Int, 2007, 27(4): 451-453. DOI: 10.1111/j.1478-3231.2007.01441.x. [106] PENG X, LUO X, HOU JY, et al. Immunosuppressive agents for the treatment of primary sclerosing cholangitis: A systematic review and Meta-analysis[J]. Dig Dis, 2017, 35(5): 478-485. DOI: 10.1159/000471874. [107] ALI AH, DAMMAN J, SHAH SB, et al. Open-label prospective therapeutic clinical trials: Oral vancomycin in children and adults with primary sclerosing cholangitis[J]. Scand J Gastroenterol, 2020, 55(8): 941-950. DOI: 10.1080/00365521.2020.1787501. [108] TABIBIAN JH, WEEDING E, JORGENSEN RA, et al. Randomised clinical trial: Vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study[J]. Aliment Pharmacol Ther, 2013, 37(6): 604-612. DOI: 10.1111/apt.12232. [109] RAHIMPOUR S, NASIRI-TOOSI M, KHALILI H, et al. A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: A pilot study[J]. J Gastrointestin Liver Dis, 2016, 25(4): 457-464. DOI: 10.15403/jgld.2014.1121.254.rah. [110] TABIBIAN JH, GOSSARD A, EL-YOUSSEF M, et al. Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis[J]. Am J Ther, 2017, 24(1): e56-e63. DOI: 10.1097/MJT.0000000000000102. [111] SHAH A, CRAWFORD D, BURGER D, et al. Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: A systematic review and Meta-analysis[J]. Semin Liver Dis, 2019, 39(4): 432-441. DOI: 10.1055/s-0039-1688501. [112] BROOMÉ U, OLSSON R, LÖÖF L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis[J]. Gut, 1996, 38(4): 610-615. DOI: 10.1136/gut.38.4.610. [113] OLSSON R, BROOMÉ U, DANIELSSON A, et al. Spontaneous course of symptoms in primary sclerosing cholangitis: Relationships with biochemical and histological features[J]. Hepatogastroenterology, 1999, 46(25): 136-141. [114] BERGQUIST A, SAID K, BROOMÉ U. Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden[J]. Scand J Gastroenterol, 2007, 42(1): 88-93. DOI: 10.1080/00365520600787994. [115] GOTTHARDT DN, RUPP C, BRUHIN M, et al. Pruritus is associated with severely impaired quality of life in patients with primary sclerosing cholangitis[J]. Eur J Gastroenterol Hepatol, 2014, 26(12): 1374-1379. DOI: 10.1097/MEG.0000000000000223. [116] KUIPER EM, van ERPECUM KJ, BEUERS U, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: Results of a double-blind, randomized, placebo-controlled trial[J]. Hepatology, 2010, 52(4): 1334-1340. DOI: 10.1002/hep.23821. [117] ATAEI S, KORD L, LARKI A, et al. Comparison of sertraline with rifampin in the treatment of cholestatic pruritus: A randomized clinical trial[J]. Rev Recent Clin Trials, 2019, 14(3): 217-223. DOI: 10.2174/1574887114666190328130720. [118] MAYO MJ, HANDEM I, SALDANA S, et al. Sertraline as a first-line treatment for cholestatic pruritus[J]. Hepatology, 2007, 45(3): 666-674. DOI: 10.1002/hep.21553. [119] de VRIES E, BOLIER R, GOET J, et al. Fibrates for Itch (FITCH) in fibrosing cholangiopathies: A double-blind, randomized, placebo-controlled trial[J]. Gastroenterology, 2021, 160(3): 734-743. DOI: 10.1053/j.gastro.2020.10.001 [120] STIEHL A, RUDOLPH G, KLÖTERS-PLACHKY P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: Outcome after endoscopic treatment[J]. J Hepatol, 2002, 36(2): 151-156. DOI: 10.1016/s0168-8278(01)00251-3. [121] CHAPMAN MH, WEBSTER GJ, BANNOO S, et al. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: A 25-year single-centre experience[J]. Eur J Gastroenterol Hepatol, 2012, 24(9): 1051-1058. DOI: 10.1097/MEG.0b013e3283554bbf. [122] BJÖRNSSON E, LINDQVIST-OTTOSSON J, ASZTELY M, et al. Dominant strictures in patients with primary sclerosing cholangitis[J]. Am J Gastroenterol, 2004, 99(3): 502-508. DOI: 10.1111/j.1572-0241.2004.04106.x. [123] van MILLIGEN de WIT AW, van BRACHT J, RAUWS EA, et al. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis[J]. Gastrointest Endosc, 1996, 44(3): 293-299. DOI: 10.1016/s0016-5107(96)70167-0. [124] GLUCK M, CANTONE NR, BRANDABUR JJ, et al. A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis[J]. J Clin Gastroenterol, 2008, 42(9): 1032-1039. DOI: 10.1097/MCG.0b013e3181646713. [125] GOTTHARDT DN, RUDOLPH G, KLÖTERS-PLACHKY P, et al. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: Outcome after long-term treatment[J]. Gastrointest Endosc, 2010, 71(3): 527-534. DOI: 10.1016/j.gie.2009.10.041. [126] PONSIOEN CY, LAM K, van MILLIGEN DE WIT AW, et al. Four years experience with short term stenting in primary sclerosing cholangitis[J]. Am J Gastroenterol, 1999, 94(9): 2403-2407. DOI: 10.1111/j.1572-0241.1999.01364.x. [127] PONSIOEN CY, ARNELO U, BERGQUIST A, et al. No superiority of stents vs balloon dilatation for dominant strictures in patients with primary sclerosing cholangitis[J]. Gastroenterology, 2018, 155(3): 752-759. DOI: 10.1053/j.gastro.2018.05.034. [128] FERREIRA M, RIBEIRO IB, DE MOURA D, et al. Stent versus balloon dilation for the treatment of dominant strictures in primary sclerosing cholangitis: A systematic review and Meta-analysis[J]. Clin Endosc, 2021, 54(6): 833-842. DOI: 10.5946/ce.2021.052. [129] RUPP C, HIPPCHEN T, BRUCKNER T, et al. Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis[J]. Gut, 2019, 68(12): 2170-2178. DOI: 10.1136/gutjnl-2018-316801. [130] SAPISOCHIN G, JAVLE M, LERUT J, et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: Working Group Report From the ILTS Transplant Oncology Consensus Conference[J]. Transplantation, 2020, 104(6): 1125-1130. DOI: 10.1097/TP.0000000000003212. [131] TAGHAVI SA, ESHRAGHIAN A, NIKNAM R, et al. Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(6): 575-584. DOI: 10.1080/17474124.2018.1473761. [132] MARTIN EF, LEVY C. Timing, management, and outcomes of liver transplantation in primary sclerosing cholangitis[J]. Semin Liver Dis, 2017, 37(4): 305-313. DOI: 10.1055/s-0037-1608655. [133] WANG J, ZHU ZJ, QU W, et al. Liver transplantation for primary sclerosing cholangitis: A single center experience[J]. J Clin Exp Med, 2019, 18(19): 2095-2097. DOI: 10.3969/j.issn.1671-4695.2019.19.023.王君, 朱志军, 曲伟, 等. 原发性硬化性胆管炎的肝移植诊治研究[J]. 临床和实验医学杂志, 2019, 18(19): 2095-2097. DOI: 10.3969/j.issn.1671-4695.2019.19.023. [134] GU J, JIANG WT, LI J, et al. Clinical analysis of liver transplantation in end-stage autoimmune liver diseases[J]. Chin Critical Care Med, 2019, 31(11): 1401-1405. DOI: 10.3760/cma.j.issn.2095-4352.2019.11.017.古杰, 蒋文涛, 李江, 等. 肝移植治疗终末期自身免疫性肝病的临床分析[J]. 中华危重病急救医学, 2019, 31(11): 1401-1405. DOI: 10.3760/cma.j.issn.2095-4352.2019.11.017. [135] STEENSTRATEN IC, SEBIB KORKMAZ K, TRIVEDI PJ, et al. Systematic review with meta-analysis: Risk factors for recurrent primary sclerosing cholangitis after liver transplantation[J]. Aliment Pharmacol Ther, 2019, 49(6): 636-643. DOI: 10.1111/apt.15148. [136] Ministry of Health of the People's Republic of China. Basic principles of human organ distribution and sharing and core policies of liver and kidney transplantation in China[J/CD]. Chin J Transplant (Electronic Edition), 2011, 5(1): 72-76.中华人民共和国卫生部. 中国人体器官分配与共享基本原则和肝脏与肾脏移植核心政策[J/CD]. 中华移植杂志(电子版), 2011, 5(1): 72-76. [137] GOLDBERG DS, FRENCH B, THOMASSON A, et al. Current trends in living donor liver transplantation for primary sclerosing cholangitis[J]. Transplantation, 2011, 91(10): 1148-1152. DOI: 10.1097/TP.0b013e31821694b3. [138] GOLDBERG DS, CAMP A, MARTINEZ-CAMACHO A, et al. Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis[J]. Liver Transpl, 2013, 19(3): 250-258. DOI: 10.1002/lt.23587. [139] ANGULO P, MAOR-KENDLER Y, LINDOR KD. Small-duct primary sclerosing cholangitis: A long-term follow-up study[J]. Hepatology, 2002, 35(6): 1494-1500. DOI: 10.1053/jhep.2002.33202. [140] EATON JE, MCCAULEY BM, ATKINSON EJ, et al. Variations in primary sclerosing cholangitis across the age spectrum[J]. J Gastroenterol Hepatol, 2017, 32(10): 1763-1768. DOI: 10.1111/jgh.13774. [141] BJÖRNSSON E, OLSSON R, BERGQUIST A, et al. The natural history of small-duct primary sclerosing cholangitis[J]. Gastroenterology, 2008, 134(4): 975-980. DOI: 10.1053/j.gastro.2008.01.042. [142] BJÖRNSSON E, BOBERG KM, CULLEN S, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis[J]. Gut, 2002, 51(5): 731-735. DOI: 10.1136/gut.51.5.731. [143] van BUUREN HR, van HOOGSTRATEN H, TERKIVATAN T, et al. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis[J]. J Hepatol, 2000, 33(4): 543-548. DOI: 10.1034/j.1600-0641.2000.033004543.x. [144] KAYA M, ANGULO P, LINDOR KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: An evaluation of a modified scoring system[J]. J Hepatol, 2000, 33(4): 537-542. DOI: 10.1034/j.1600-0641.2000.033004537.x. [145] LVTH S, KANZLER S, FRENZEL C, et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome[J]. J Clin Gastroenterol, 2009, 43(1): 75-80. DOI: 10.1097/MCG.0b013e318157c614. [146] GREGORIO GV, PORTMANN B, KARANI J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16-year prospective study[J]. Hepatology, 2001, 33(3): 544-553. DOI: 10.1053/jhep.2001.22131. [147] OLSSON R, GLAUMANN H, ALMER S, et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis[J]. Eur J Intern Med, 2009, 20(2): 190-196. DOI: 10.1016/j.ejim.2008.06.004. [148] DENEAU MR, EL-MATARY W, VALENTINO PL, et al. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration[J]. Hepatology, 2017, 66(2): 518-527. DOI: 10.1002/hep.29204. [149] DENEAU M, JENSEN MK, HOLMEN J, et al. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: Epidemiology and natural history[J]. Hepatology, 2013, 58(4): 1392-1400. DOI: 10.1002/hep.26454. [150] MILOH T, ARNON R, SHNEIDER B, et al. A retrospective single-center review of primary sclerosing cholangitis in children[J]. Clin Gastroenterol Hepatol, 2009, 7(2): 239-245. DOI: 10.1016/j.cgh.2008.10.019. [151] FELDSTEIN AE, PERRAULT J, EL-YOUSSIF M, et al. Primary sclerosing cholangitis in children: A long-term follow-up study[J]. Hepatology, 2003, 38(1): 210-217. DOI: 10.1053/jhep.2003.50289. [152] FERRARI F, RANUCCI G, ALOI M, et al. A promising medium-term follow-up of pediatric sclerosing cholangitis: Mild phenotype or early diagnosis?[J]. Hepatol Res, 2018, 48(7): 556-565. DOI: 10.1111/hepr.13059. [153] WIECEK S, WOJTYNIAK A, PINDUR B, et al. Analysis of the clinical course of primary sclerosing cholangitis in paediatric population-single center study[J]. Medicina (Kaunas), 2021, 57(7): 663. DOI: 10.3390/medicina57070663. [154] DENEAU MR, MACK C, PERITO ER, et al. The sclerosing cholangitis outcomes in pediatrics (SCOPE) index: A prognostic tool for children[J]. Hepatology, 2021, 73(3): 1074-1087. DOI: 10.1002/hep.31393. [155] DENEAU MR, MACK C, MOGUL D, et al. Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis: A matched analysis[J]. Hepatology, 2021, 73(3): 1061-1073. DOI: 10.1002/hep.31560. [156] DENEAU MR, MACK C, ABDOU R, et al. Gamma glutamyltransferase reduction is associated with favorable outcomes in pediatric primary sclerosing cholangitis[J]. Hepatol Commun, 2018, 2(11): 1369-1378. DOI: 10.1002/hep4.1251. [157] DENEAU M, PERITO E, RICCIUTO A, et al. Ursodeoxycholic acid therapy in pediatric primary sclerosing cholangitis: Predictors of gamma glutamyltransferase normalization and favorable clinical course[J]. J Pediatr, 2019, 209: 92-96. e1. DOI: 10.1016/j.jpeds.2019.01.039. [158] TAKAKURA WR, TABIBIAN JH, BOWLUS CL. The evolution of natural history of primary sclerosing cholangitis[J]. Curr Opin Gastroenterol, 2017, 33(2): 71-77. DOI: 10.1097/MOG.0000000000000333. [159] ADIKE A, CAREY EJ, LINDOR KD. Primary sclerosing cholangitis in children versus adults: Lessons for the clinic[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(10): 1025-1032. DOI: 10.1080/17474124.2018.1521719. [160] EATON JE, VESTERHUS M, MCCAULEY BM, et al. Primary sclerosing cholangitis risk estimate tool (PREsTo) predicts outcomes of the disease: A derivation and validation study using machine learning[J]. Hepatology, 2020, 71(1): 214-224. DOI: 10.1002/hep.30085. [161] GOODE EC, CLARK AB, MELLS GF, et al. Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system[J]. Hepatology, 2019, 69(5): 2120-2135. DOI: 10.1002/hep.30479. [162] de VRIES EM, de KRIJGER M, FÄRKKILÄ M, et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study[J]. Hepatology, 2017, 65(3): 907-919. DOI: 10.1002/hep.28963. [163] de VRIES EM, WANG J, WILLIAMSON KD, et al. A novel prognostic model for transplant-free survival in primary sclerosing cholangitis[J]. Gut, 2018, 67(10): 1864-1869. DOI: 10.1136/gutjnl-2016-313681. [164] TANAKA A, MORI M, KUBOTA K, et al. Epidemiological features of immunoglobulin G4-related sclerosing cholangitis in Japan[J]. J Hepatobiliary Pancreat Sci, 2020, 27(9): 598-603. DOI: 10.1002/jhbp.793. [165] TANAKA A, TAZUMA S, OKAZAKI K, et al. Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 920-926. e3. DOI: 10.1016/j.cgh.2016.12.038. [166] ALI AH, BI Y, MACHICADO JD, et al. The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: The Mayo Clinic experience[J]. J Gastroenterol, 2020, 55(11): 1087-1097. DOI: 10.1007/s00535-020-01714-7. [167] LIAN M, LI B, XIAO X, et al. Comparative clinical characteristics and natural history of three variants of sclerosing cholangitis: IgG4-related SC, PSC/AIH and PSC alone[J]. Autoimmun Rev, 2017, 16(8): 875-882. DOI: 10.1016/j.autrev.2017.05.018. [168] JIANG P, LIAN M, LI B, et al. Clinical observation of isolated immunoglobulin G4-related sclerosing cholangitis and immunoglobulin G4 sclerosing cholangitis combined autoimmune pancreatitis[J]. Chin J Hepatol, 2018, 26(6): 415-419. DOI: 10.3760/cma.j.issn.1007-3418.2018.06.005.姜畔, 连敏, 李博, 等. 免疫球蛋白G4相关硬化性胆管炎及合并自身免疫性胰腺炎患者的临床观察[J]. 中华肝脏病杂志, 2018, 26(6): 415-419. DOI: 10.3760/cma.j.issn.1007-3418.2018.06.005. [169] XIAO J, XU P, LI B, et al. Analysis of clinical characteristics and treatment of immunoglobulin G4-associated cholangitis: A retrospective cohort study of 39 IAC patients[J]. Medicine (Baltimore), 2018, 97(8): e9767. DOI: 10.1097/MD.0000000000009767. [170] NAKAZAWA T, OHARA H, SANO H, et al. Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography[J]. Pancreas, 2006, 32(2): 229. DOI: 10.1097/01.mpa.0000202941.85955.07. [171] MO Z, RAMEN K, SHAN Y, et al. Localized intrahepatic IgG4-related sclerosing cholangitis (IgG4-SC) as an additional type of IgG4-SC: A systematic analysis of 12 cases[J]. Scand J Gastroenterol, 2018, 53(3): 312-318. DOI: 10.1080/00365521.2018.1424233. [172] GHAZALE A, CHARI ST, ZHANG L, et al. Immunoglobulin G4-associated cholangitis: Clinical profile and response to therapy[J]. Gastroenterology, 2008, 134(3): 706-715. DOI: 10.1053/j.gastro.2007.12.009. [173] HUGGETT MT, CULVER EL, KUMAR M, et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort[J]. Am J Gastroenterol, 2014, 109(10): 1675-1683. DOI: 10.1038/ajg.2014.223. [174] KURITA Y, FUJITA Y, SEKINO Y, et al. IgG4-related sclerosing cholangitis may be a risk factor for cancer[J]. J Hepatobiliary Pancreat Sci, 2021, 28(6): 524-532. DOI: 10.1002/jhbp.957. [175] MADHUSUDHAN KS, DAS P, GUNJAN D, et al. IgG4-related sclerosing cholangitis: A clinical and imaging review[J]. AJR Am J Roentgenol, 2019, 213(6): 1221-1231. DOI: 10.2214/AJR.19.21519. [176] OHARA H, NAKAZAWA T, KAWA S, et al. Establishment of a serum IgG4 cut-off value for the differential diagnosis of IgG4-related sclerosing cholangitis: A Japanese cohort[J]. J Gastroenterol Hepatol, 2013, 28(7): 1247-1251. DOI: 10.1111/jgh.12248. [177] OSEINI AM, CHAITEERAKIJ R, SHIRE AM, et al. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma[J]. Hepatology, 2011, 54(3): 940-948. DOI: 10.1002/hep.24487. [178] KÖBEL M, KALLOGER SE, BAKER PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: A transcanadian study[J]. Am J Surg Pathol, 2010, 34(7): 984-993. DOI: 10.1097/PAS.0b013e3181e1a3bb. [179] BOONSTRA K, CULVER EL, de BUY WENNIGER LM, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis[J]. Hepatology, 2014, 59(5): 1954-1963. DOI: 10.1002/hep.26977. [180] TANAKA A, TAZUMA S, NAKAZAWA T, et al. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan[J]. J Hepatobiliary Pancreat Sci, 2017, 24(4): 217-225. DOI: 10.1002/jhbp.432. [181] BJÖRNSSON E, CHARI S, SILVEIRA M, et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: Clinical characteristics and response to therapy[J]. Am J Ther, 2011, 18(3): 198-205. DOI: 10.1097/MJT.0b013e3181c9dac6. [182] ALSWAT K, AL-HARTHY N, MAZRANI W, et al. The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice[J]. Am J Gastroenterol, 2012, 107(1): 56-63. DOI: 10.1038/ajg.2011.375. [183] BERNTSEN NL, KLINGENBERG O, JURAN BD, et al. Association between HLA haplotypes and increased serum levels of IgG4 in patients with primary sclerosing cholangitis[J]. Gastroenterology, 2015, 148(5): 924-927. e2. DOI: 10.1053/j.gastro.2015.01.041. [184] BENITO de VALLE M, MVLLER T, BJÖRNSSON E, et al. The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis[J]. Dig Liver Dis, 2014, 46(10): 903-908. DOI: 10.1016/j.dld.2014.06.010. [185] NGWA TN, LAW R, MURRAY D, et al. Serum immunoglobulin G4 level is a poor predictor of immunoglobulin G4-related disease[J]. Pancreas, 2014, 43(5): 704-707. DOI: 10.1097/MPA.0000000000000118. [186] OKAZAKI K, UCHIDA K, FUKUI T. Recent advances in autoimmune pancreatitis: Concept, diagnosis, and pathogenesis[J]. J Gastroenterol, 2008, 43(6): 409-418. DOI: 10.1007/s00535-008-2190-9. [187] SAH RP, PANNALA R, ZHANG L, et al. Eosinophilia and allergic disorders in autoimmune pancreatitis[J]. Am J Gastroenterol, 2010, 105(11): 2485-2491. DOI: 10.1038/ajg.2010.236. [188] KAMISAWA T, ANJIKI H, EGAWA N, et al. Allergic manifestations in autoimmune pancreatitis[J]. Eur J Gastroenterol Hepatol, 2009, 21(10): 1136-1139. DOI: 10.1097/meg.0b013e3283297417. [189] KOYAMA R, IMAMURA T, OKUDA C, et al. Ultrasonographic imaging of bile duct lesions in autoimmune pancreatitis[J]. Pancreas, 2008, 37(3): 259-264. DOI: 10.1097/MPA.0b013e31816b30e7. [190] DU S, LIU G, CHENG X, et al. Differential diagnosis of immunoglobulin G4-associated cholangitis from cholangiocarcinoma[J]. J Clin Gastroenterol, 2016, 50(6): 501-505. DOI: 10.1097/MCG.0000000000000509. [191] FENG Y, ZHANG S, ZHENG Z, et al. Biliary inflammation scoring for immunoglobulin G4-related sclerosing cholangitis: An endoscopic approach with endoscopic ultrasound[J]. Surg Endosc, 2021, 35(12): 7068-7073. DOI: 10.1007/s00464-020-08222-y. [192] TOKALA A, KHALILI K, MENEZES R, et al. Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis[J]. AJR Am J Roentgenol, 2014, 202(3): 536-543. DOI: 10.2214/AJR.12.10360. [193] YATA M, SUZUKI K, FURUHASHI N, et al. Comparison of the multidetector-row computed tomography findings of IgG4-related sclerosing cholangitis and extrahepatic cholangiocarcinoma[J]. Clin Radiol, 2016, 71(3): 203-210. DOI: 10.1016/j.crad.2015.10.024. [194] MAEDA E, AKAHANE M, YOSHIOKA N, et al. Comparison of CT findings of biliary tract changes with autoimmune pancreatitis and extrahepatic bile duct cholangiocarcinoma[J]. Jpn J Radiol, 2012, 30(3): 227-234. DOI: 10.1007/s11604-011-0035-6. [195] ITOH S, NAGASAKA T, SUZUKI K, et al. Lymphoplasmacytic sclerosing cholangitis: Assessment of clinical, CT, and pathological findings[J]. Clin Radiol, 2009, 64(11): 1104-1114. DOI: 10.1016/j.crad.2009.07.006. [196] NAITOH I, NAKAZAWA T, OHARA H, et al. Endoscopic transpapillary intraductal ultrasonography and biopsy in the diagnosis of IgG4-related sclerosing cholangitis[J]. J Gastroenterol, 2009, 44(11): 1147-1155. DOI: 10.1007/s00535-009-0108-9. [197] HYODO N, HYODO T. Ultrasonographic evaluation in patients with autoimmune-related pancreatitis[J]. J Gastroenterol, 2003, 38(12): 1155-1161. DOI: 10.1007/s00535-003-1223-7. [198] OHARA H, OKAZAKI K, TSUBOUCHI H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012[J]. J Hepatobiliary Pancreat Sci, 2012, 19(5): 536-542. DOI: 10.1007/s00534-012-0521-y. [199] MOON SH, KIM MH. The role of endoscopy in the diagnosis of autoimmune pancreatitis[J]. Gastrointest Endosc, 2012, 76(3): 645-656. DOI: 10.1016/j.gie.2012.04.458. [200] TABATA T, KAMISAWA T, HARA S, et al. Differentiating immunoglobulin g4-related sclerosing cholangitis from hilar cholangiocarcinoma[J]. Gut Liver, 2013, 7(2): 234-238. DOI: 10.5009/gnl.2013.7.2.234. [201] KUWATANI M, KAWAKAMI H, ZEN Y, et al. Difference from bile duct cancer and relationship between bile duct wall thickness and serum IgG/IgG4 levels in IgG4-related sclerosing cholangitis[J]. Hepatogastroenterology, 2014, 61(135): 1852-1856. [202] KAMISAWA T, OKAZAKI K. Role of endoscopic retrograde cholangiography in autoimmune pancreatitis[J]. Pancreatology, 2016, 16(5): 798-799. DOI: 10.1016/j.pan.2016.06.003. [203] NAITOH I, ZEN Y, NAKAZAWA T, et al. Small bile duct involvement in IgG4-related sclerosing cholangitis: Liver biopsy and cholangiography correlation[J]. J Gastroenterol, 2011, 46(2): 269-276. DOI: 10.1007/s00535-010-0319-0. [204] KUBOTA K, KATO S, UCHIYAMA T, et al. Discrimination between sclerosing cholangitis-associated autoimmune pancreatitis and primary sclerosing cholangitis, cancer using intraductal ultrasonography[J]. Dig Endosc, 2011, 23(1): 10-16. DOI: 10.1111/j.1443-1661.2010.01039.x. [205] NAITOH I, NAKAZAWA T, HAYASHI K, et al. Comparison of intraductal ultrasonography findings between primary sclerosing cholangitis and IgG4-related sclerosing cholangitis[J]. J Gastroenterol Hepatol, 2015, 30(6): 1104-1109. DOI: 10.1111/jgh.12894. [206] NAITOH I, KAMISAWA T, TANAKA A, et al. Clinical characteristics of immunoglobulin IgG4-related sclerosing cholangitis: Comparison of cases with and without autoimmune pancreatitis in a large cohort[J]. Dig Liver Dis, 2021, 53(10): 1308-1314. DOI: 10.1016/j.dld.2021.02.009. [207] ITOI T, KAMISAWA T, IGARASHI Y, et al. The role of peroral video cholangioscopy in patients with IgG4-related sclerosing cholangitis[J]. J Gastroenterol, 2013, 48(4): 504-514. DOI: 10.1007/s00535-012-0652-6. [208] ITOI T, SOFUNI A, ITOKAWA F, et al. Peroral cholangioscopic diagnosis of biliary-tract diseases by using narrow-band imaging (with videos)[J]. Gastrointest Endosc, 2007, 66(4): 730-736. DOI: 10.1016/j.gie.2007.02.056. [209] ZEN Y, HARADA K, SASAKI M, et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: Do they belong to a spectrum of sclerosing pancreatitis?[J]. Am J Surg Pathol, 2004, 28(9): 1193-1203. DOI: 10.1097/01.pas.0000136449.37936.6c. [210] HIRANO K, TADA M, ISAYAMA H, et al. Endoscopic evaluation of factors contributing to intrapancreatic biliary stricture in autoimmune pancreatitis[J]. Gastrointest Endosc, 2010, 71(1): 85-90. DOI: 10.1016/j.gie.2009.08.008. [211] KAWAKAMI H, ZEN Y, KUWATANI M, et al. IgG4-related sclerosing cholangitis and autoimmune pancreatitis: Histological assessment of biopsies from Vater's ampulla and the bile duct[J]. J Gastroenterol Hepatol, 2010, 25(10): 1648-1655. DOI: 10.1111/j.1440-1746.2010.06346.x. [212] UNNO H, SAEGUSA H, FUKUSHIMA M, et al. Usefulness of endoscopic observation of the main duodenal papilla in the diagnosis of sclerosing pancreatitis[J]. Gastrointest Endosc, 2002, 56(6): 880-884. DOI: 10.1067/mge.2002.129605. [213] KAMISAWA T, TU Y, NAKAJIMA H, et al. Usefulness of biopsying the major duodenal papilla to diagnose autoimmune pancreatitis: A prospective study using IgG4-immunostaining[J]. World J Gastroenterol, 2006, 12(13): 2031-2033. DOI: 10.3748/wjg.v12.i13.2031. [214] SEPEHR A, MINO-KENUDSON M, OGAWA F, et al. IgG4+ to IgG+ plasma cells ratio of ampulla can help differentiate autoimmune pancreatitis from other "mass forming" pancreatic lesions[J]. Am J Surg Pathol, 2008, 32(12): 1770-1779. DOI: 10.1097/PAS.0b013e318185490a. [215] KAWA S, OKAZAKI K, KAMISAWA T, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: Ⅱ. Extrapancreatic lesions, differential diagnosis[J]. J Gastroenterol, 2010, 45(4): 355-369. DOI: 10.1007/s00535-009-0197-5. [216] NAITOH I, NAKAZAWA T. Endoscopic retrograde cholangiopancreatography and intraductal ultrasonography in the diagnosis of autoimmune pancreatitis and IgG4-related sclerosing cholangitis[J]. J Med Ultrason (2001), 2021, 48(4): 573-580. DOI: 10.1007/s10396-021-01114-1. [217] DESHPANDE V, SAINANI NI, CHUNG RT, et al. IgG4-associated cholangitis: A comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material[J]. Mod Pathol, 2009, 22(10): 1287-1295. DOI: 10.1038/modpathol.2009.94. [218] NAKAZAWA T, OHARA H, SANO H, et al. Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis[J]. Pancreas, 2005, 30(1): 20-25. [219] NISHINO T, OYAMA H, HASHIMOTO E, et al. Clinicopathological differentiation between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis[J]. J Gastroenterol, 2007, 42(7): 550-559. DOI: 10.1007/s00535-007-2038-8. [220] STONE JH, KHOSROSHAHI A, DESHPANDE V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations[J]. Arthritis Rheum, 2012, 64(10): 3061-3067. DOI: 10.1002/art.34593. [221] WATANABE T, MARUYAMA M, ITO T, et al. Mechanisms of lower bile duct stricture in autoimmune pancreatitis[J]. Pancreas, 2014, 43(2): 255-260. DOI: 10.1097/01.mpa.0000437323.52598.20. [222] MIYABEK, ZENY, CORNELLLD, et al. Gastrointestinal and extra-intestinal manifestations of IgG4-related disease[J]. Gastroenterology, 2018, 155(4): 990-1003. e1. DOI: 10.1053/j.gastro.2018.06.082. [223] RAGLIANTI V, ROSSI GM, VAGLIO A. Idiopathic retroperitoneal fibrosis: An update for nephrologists[J]. Nephrol Dial Transplant, 2021, 36(10): 1773-1781. DOI: 10.1093/ndt/gfaa083. [224] KUBO K, YAMAMOTO K. IgG4-related disease[J]. Int J Rheum Dis, 2016, 19(8): 747-762. DOI: 10.1111/1756-185X.12586. [225] OHARA H, OKAZAKI K, TSUBOUCHI H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012[J]. J Hepatobiliary Pancreat Sci, 2012, 19(5): 536-542. DOI: 10.1007/s00534-012-0521-y. [226] NAKAZAWA T, KAMISAWA T, OKAZAKI K, et al. Clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2020: (Revision of the clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2012)[J]. J Hepatobiliary Pancreat Sci, 2021, 28(3): 235-242. DOI: 10.1002/jhbp.913. [227] KALAITZAKIS E, LEVY M, KAMISAWA T, et al. Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma[J]. Clin Gastroenterol Hepatol, 2011, 9(9): 800-803. e2. DOI: 10.1016/j.cgh.2011.05.019. [228] GARDNER CS, BASHIR MR, MARIN D, et al. Diagnostic performance of imaging criteria for distinguishing autoimmune cholangiopathy from primary sclerosing cholangitis and bile duct malignancy[J]. Abdom Imaging, 2015, 40(8): 3052-3061. DOI: 10.1007/s00261-015-0543-4. [229] NAKAZAWA T, NAITOH I, HAYASHI K, et al. Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification[J]. J Gastroenterol, 2012, 47(1): 79-87. DOI: 10.1007/s00535-011-0465-z. [230] SANO H, NAKAZAWA T, ANDO T, et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis[J]. J Hepatobiliary Pancreat Sci, 2011, 18(2): 154-161. DOI: 10.1007/s00534-010-0319-8. [231] SHIMOSEGAWA T, CHARI ST, FRULLONI L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: Guidelines of the International Association of Pancreatology[J]. Pancreas, 2011, 40(3): 352-358. DOI: 10.1097/MPA.0b013e3182142fd2. [232] IWASAKI S, KAMISAWA T, KOIZUMI S, et al. Assessment in steroid trial for IgG4-related sclerosing cholangitis[J]. Adv Med Sci, 2015, 60(2): 211-215. DOI: 10.1016/j.advms.2015.02.006. [233] KAMISAWA T, OKAZAKI K, KAWA S, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 Ⅲ. Treatment and prognosis of autoimmune pancreatitis[J]. J Gastroenterol, 2014, 49(6): 961-970. DOI: 10.1007/s00535-014-0945-z. [234] GHAZALE A, CHARI ST. Optimising corticosteroid treatment for autoimmune pancreatitis[J]. Gut, 2007, 56(12): 1650-1652. DOI: 10.1136/gut.2007.129833. [235] KAMISAWA T, SHIMOSEGAWA T, OKAZAKI K, et al. Standard steroid treatment for autoimmune pancreatitis[J]. Gut, 2009, 58(11): 1504-1507. DOI: 10.1136/gut.2008.172908. [236] BUIJS J, van HEERDE MJ, RAUWS EA, et al. Comparable efficacy of low-versus high-dose induction corticosteroid treatment in autoimmune pancreatitis[J]. Pancreas, 2014, 43(2): 261-267. DOI: 10.1097/MPA.0000000000000044. [237] MATSUSHITA M, YAMASHINA M, IKEURA T, et al. Effective steroid pulse therapy for the biliary stenosis caused by autoimmune pancreatitis[J]. Am J Gastroenterol, 2007, 102(1): 220-221. [238] TOMIYAMA T, UCHIDA K, MATSUSHITA M, et al. Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis[J]. J Gastroenterol, 2011, 46(5): 696-704. DOI: 10.1007/s00535-010-0361-y. [239] MASAMUNE A, NISHIMORI I, KIKUTA K, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis[J]. Gut, 2017, 66(3): 487-494. DOI: 10.1136/gutjnl-2016-312049. [240] KUBOTA K, KAMISAWA T, OKAZAKI K, et al. Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: A long-term Japanese multicenter analysis of 510 patients[J]. J Gastroenterol, 2017, 52(8): 955-964. DOI: 10.1007/s00535-016-1302-1. [241] HIRANO K, TADA M, ISAYAMA H, et al. Outcome of long-term maintenance steroid therapy cessation in patients with autoimmune pancreatitis: A prospective study[J]. J Clin Gastroenterol, 2016, 50(4): 331-337. DOI: 10.1097/MCG.0000000000000440. [242] SANDANAYAKE NS, CHURCH NI, CHAPMAN MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis[J]. Clin Gastroenterol Hepatol, 2009, 7(10): 1089-1096. DOI: 10.1016/j.cgh.2009.03.021. [243] HART PA, TOPAZIAN MD, WITZIG TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: The Mayo Clinic experience[J]. Gut, 2013, 62(11): 1607-1615. DOI: 10.1136/gutjnl-2012-302886. [244] KAMISAWA T, KURUMA S, CHIBA K. The treatment of IgG4-related diseases in the hepatobiliary-pancreatic system[J]. Semin Liver Dis, 2016, 36(3): 291-296. DOI: 10.1055/s-0036-1584324. [245] HART PA, KAMISAWA T, BRUGGE WR, et al. Long-term outcomes of autoimmune pancreatitis: A multicentre, international analysis[J]. Gut, 2013, 62(12): 1771-1776. DOI: 10.1136/gutjnl-2012-303617. [246] YOU MW, KIM JH, BYUN JH, et al. Relapse of IgG4-related sclerosing cholangitis after steroid therapy: Image findings and risk factors[J]. Eur Radiol, 2014, 24(5): 1039-1048. DOI: 10.1007/s00330-014-3127-8. [247] TOPAZIAN M, WITZIG TE, SMYRK TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis[J]. Clin Gastroenterol Hepatol, 2008, 6(3): 364-366. DOI: 10.1016/j.cgh.2007.12.020. [248] KHOSROSHAHI A, BLOCH DB, DESHPANDE V, et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease[J]. Arthritis Rheum, 2010, 62(6): 1755-1762. DOI: 10.1002/art.27435. [249] CARRUTHERS MN, TOPAZIAN MD, KHOSROSHAHI A, et al. Rituximab for IgG4-related disease: A prospective, open-label trial[J]. Ann Rheum Dis, 2015, 74(6): 1171-1177. DOI: 10.1136/annrheumdis-2014-206605. -
本文二维码
表(4)
计量
- 文章访问数: 1622
- HTML全文浏览量: 238
- PDF下载量: 613
- 被引次数: 0
